YL-13027 + gemcitabine + nab-paclitaxel

YL-13027 + gemcitabine + nab-paclitaxel is a combination investigational therapy for cancer that incorporates three agents: - **YL-13027** is an orally available, potent, selective small molecule inhibitor of transforming growth factor beta receptor 1 (TGFβR1), a serine/threonine kinase implicated in tumor cell proliferation, modulation of the tumor microenvironment, and metastasis. It acts as an antagonist of TGFβR1-dependent signaling and has demonstrated anti-tumor efficacy and tolerability in early clinical studies for advanced solid tumors and pancreatic cancer. - **Gemcitabine** is a nucleoside analog and antimetabolite widely used as chemotherapy in various cancers, working primarily by inhibiting DNA synthesis during cell division. - **Nab-paclitaxel** is an albumin-bound formulation of paclitaxel (a microtubule-stabilizing taxane), designed for intravenous delivery, commonly combined with gemcitabine to treat advanced or metastatic pancreatic cancer and other solid tumors. This triple combination is being investigated primarily for advanced solid tumors, including metastatic pancreatic adenocarcinoma, with the rationale that YL-13027 may modulate the tumor microenvironment to improve the efficacy of standard chemotherapies gemcitabine and nab-paclitaxel[1][2][3][4].